MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
MCE 国际站:Anti-COVID-19 Compound Library
COVID-19 poses a serious threat to people's health, and it is urgent to develop drugs to treat COVID-19 quickly. The screening of anti-COVID-19 drugs by using the clinical and approved compounds can greatly shorten the research and development cycle. In addition, the virtual screening technology can effectively narrow the scope of screening and improve the screening efficiency in the pre-screening of new drugs.Taking advantage of our virtual screening, we conduct virtual screening of approved compound library and clinical compound library based on the 3CL protease (PDB ID: 6LU7), Spike Glycoprotein (PDB ID: 6VSB), NSP15 (PDB ID: 6VWW), RDRP, PLPro and ACE2 (Angiotensin Converting Enzyme 2) structure. We design a unique collection of 1473 compounds which may have anti-COVID-19 activity. Anti-COVID-19 Compound Library will be a powerful tool for screening new anti-COVID-19 activity drugs.
Description & Advantages:
• A unique collection of 1473 compounds that may have anti-COVID-19 activity for high throughput screening (HTS) and high content screening (HCS).
• All compounds are derived from virtual screening of approved compound library and clinical compound library based on the 3CL protease, Spike Glycoprotein and ACE2 structure.
• A useful tool for the development of anti-COVID-19 drugs.
• Bioactivity and safety confirmed by preclinical research and clinical trials.
• Structurally diverse, medicinally active, and cell permeable.
• More detailed compound information with structure, IC50, and brief introduction.
• NMR and HPLC validated to ensure high purity and quality.
• All compounds are in stock and continuously updated.